Joseph Thome

Brian Abrahams

Brian Skorney

Jason Gerberry

Andrew Tsai

Paul Choi

Paul Matteis

Sarah Schram

Tessa Romero

Basma Radwan

Basma Radwan Ibrahim

Caroline Kimberly Pocher

Cory Kasimov

Danielle Brill

Dina Ramadane

Douglas Tsao

Dylan Shindler

Emily Chudy

Kyuwon Choi

Lin Tsai

Marc Goodman

Matt Marcus

Myles Minter

Nevin

- Xenon Pharmaceuticals has initiated **two Phase I clinical trials** this year for its non-opioid pain programs, featuring the lead NAV1.7 inhibitor **XEN1701** and the lead KV7 potentiator **XEN1120**.  **[1582313_2169310_1]** **[1582313_2169310_3]** **[1582313_2169310_13]** 
- The company plans to advance these programs into **Phase II proof-of-concept studies next year**, with potential targets including acute pain models such as bunionectomy or abdominoplasty.  **[1582313_2169310_13]** **[1582313_2169310_17]** 
- Xenon Pharmaceuticals' lead NAV1.7 inhibitor, XEN1701, is designed to overcome prior limitations through **CNS penetrance, improved free fraction, and high selectivity**, aiming for a therapeutic profile that aligns with genetic data suggesting **75% to 85% NAV1.7 receptor occupancy is sufficient for complete pain loss**.  **[1582313_2169310_8]** **[1582313_2169310_10]** **[1582313_2169310_11]**

Xenon Pharmaceuticals Advances Non-Opioid Pain Programs into Phase I Clinical Trials

Xenon Pharmaceuticals (XENE)